Analyst Michael Matson from Needham reiterated a Buy rating on TransMedics Group and keeping the price target at $166.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Buy rating due to a combination of factors tied to stronger‑than‑expected transplant activity and revenue potential. January 2026 transplant procedures using TransMedics’ platform appear to have exceeded the company’s recent quarterly average, suggesting robust demand and continued adoption of its technology.
Extrapolating January’s pace implies meaningful year‑over‑year growth in U.S. transplant volumes and sales, with projected revenue surpassing current consensus estimates. While he acknowledges that the data reflect only one month and could be revised or slow later in the quarter, the upside versus expectations supports maintaining a positive stance on the shares.
In another report released on February 17, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.